Probing Riboswitch Binding Sites with Molecular Docking, Focused Libraries, and In-line Probing Assays

  • Francesco Colizzi
  • Anne-Marie Lamontagne
  • Daniel A. Lafontaine
  • Giovanni Bussi
Part of the Methods in Molecular Biology book series (MIMB, volume 1103)


Molecular docking calculations combined with chemically focused libraries can bring insight in the exploration of the structure–activity relationships for a series of related compounds against an RNA target. Yet, the in silico engine must be fueled by experimental observations to drive the research into a more effective ligand-discovery path. Here we show how molecular docking predictions can be coupled with in-line probing assays to explore the available chemical and configurational space in a riboswitch binding pocket.

Key words

Structure-based Ligand design Virtual screening Structure–activity relationship (SAR) Docking Focused library In-line probing 



This work was supported by the National Sciences and Engineering Research Council of Canada (NSERC). D.A.L. is a Canadian Institutes of Health Research (CIHR) New Investigator Scholar. F.C. was supported by the “Young SISSA Scientist” grant (FISB.647 2011) for independent research development. F.C. and G.B. acknowledge the European Research Council for funding through the Starting Grant S-RNA-S (no. 306662).


  1. 1.
    Guha R (2013) On exploring structure-activity relationships. Methods Mol Biol 993:81–94. doi:  10.1007/978-1-62703-342-8_6 Google Scholar
  2. 2.
    Bleicher KH, Bohm HJ, Muller K, Alanine AI (2003) Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov 2:369–378PubMedCrossRefGoogle Scholar
  3. 3.
    Jorgensen WL (2004) The many roles of computation in drug discovery. Science 303:1813–1818PubMedCrossRefGoogle Scholar
  4. 4.
    Shoichet BK (2004) Virtual screening of chemical libraries. Nature 432:862–865PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Orry AJ, Abagyan RA, Cavasotto CN (2006) Structure-based development of target-specific compound libraries. Drug Discov Today 11:261–266PubMedCrossRefGoogle Scholar
  6. 6.
    Leach AR, Hann MM (2000) The in silico world of virtual libraries. Drug Discov Today 5:326–336PubMedCrossRefGoogle Scholar
  7. 7.
    Valler MJ, Green D (2000) Diversity screening versus focussed screening in drug discovery. Drug Discov Today 5:286–293PubMedCrossRefGoogle Scholar
  8. 8.
    Villar HO, Koehler RT (2000) Comments on the design of chemical libraries for screening. Mol Divers 5:13–24PubMedCrossRefGoogle Scholar
  9. 9.
    Mulhbacher J, Brouillette E, Allard M, Fortier LC, Malouin F, Lafontaine DA (2010) Novel riboswitch ligand analogs as selective inhibitors of guanine-related metabolic pathways. PLoS Pathog 6:e1000865PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Irwin JJ, Shoichet BK (2005) ZINC – a free database of commercially available compounds for virtual screening. J Chem Inf Model 45:177–182PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Irwin JJ, Sterling T, Mysinger MM, Bolstad ES Coleman RG (2012) ZINC: a free tool to discover chemistry for biology. J Chem Inf Model (Epub ahead of print)Google Scholar
  12. 12.
    Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267:727–748PubMedCrossRefGoogle Scholar
  13. 13.
    Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD (2003) Improved protein-ligand docking using GOLD. Proteins 52:609–23PubMedCrossRefGoogle Scholar
  14. 14.
    Li Y, Shen J, Sun X, Li W, Liu G, Tang Y (2010) Accuracy assessment of protein-based docking programs against RNA targets. J Chem Inf Model 50:1134–1146PubMedCrossRefGoogle Scholar
  15. 15.
    Batey RT, Gilbert SD, Montange RK (2004) Structure of a natural guanine-responsive riboswitch complexed with the metabolite hypoxanthine. Nature 432:411–415PubMedCrossRefGoogle Scholar
  16. 16.
    Irwin JJ, Shoichet BK, Mysinger MM, Huang N, Colizzi F, Wassam P, Cao Y (2009) Automated docking screens: a feasibility study. J Med Chem 52:5712–5720PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Mysinger MM, Carchia M, Irwin JJ, Shoichet BK (2012) Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J Med Chem 55:6582–6594PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Serganov A, Yuan YR, Pikovskaya O, Polonskaia A, Malinina L, Phan AT, Hobartner C, Micura R, Breaker RR, Patel DJ (2004) Structural basis for discriminative regulation of gene expression by adenine- and guanine-sensing mRNAs. Chem Biol 11:1729–1741PubMedCrossRefGoogle Scholar
  19. 19.
    Mandal M, Boese B, Barrick JE, Winkler WC, Breaker RR (2003) Riboswitches control fundamental biochemical pathways in Bacillus subtilis and other bacteria. Cell 113:577–586PubMedCrossRefGoogle Scholar
  20. 20.
    Bissantz C, Kuhn B, Stahl M (2010) A medicinal chemist’s guide to molecular interactions. J Med Chem 53:5061–5084PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Muller K, Faeh C, Diederich F (2007) Fluorine in pharmaceuticals: looking beyond intuition. Science 317:1881–1886PubMedCrossRefGoogle Scholar
  22. 22.
    Voth AR, Khuu P, Oishi K, Ho PS (2009) Halogen bonds as orthogonal molecular interactions to hydrogen bonds. Nat Chem 1:74–79PubMedCrossRefGoogle Scholar
  23. 23.
    Gilbert SD, Reyes FE, Edwards AL, Batey RT (2009) Adaptive ligand binding by the purine riboswitch in the recognition of guanine and adenine analogs. Structure 17:857–868PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Mandal M, Breaker RR (2004) Adenine riboswitches and gene activation by disruption of a transcription terminator. Nat Struct Mol Biol 11:29–35PubMedCrossRefGoogle Scholar
  25. 25.
    Irwin JJ, Raushel FM, Shoichet BK (2005) Virtual screening against metalloenzymes for inhibitors and substrates. Biochemistry 44:12316–12328PubMedCrossRefGoogle Scholar
  26. 26.
    Milletti F, Vulpetti A (2010) Tautomer preference in PDB complexes and its impact on structure-based drug discovery. J Chem Inf Model 50:1062–1074PubMedCrossRefGoogle Scholar
  27. 27.
    Martin YC (2009) Let’s not forget tautomers. J Comput Aided Mol Des 23:693–704PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14(33–8):27–28Google Scholar
  29. 29.
    Bohm HJ, Banner D, Bendels S, Kansy M, Kuhn B, Muller K, Obst-Sander U, Stahl M (2004) Fluorine in medicinal chemistry. Chembiochem 5:637–643PubMedCrossRefGoogle Scholar
  30. 30.
    Wuitschik G, Carreira EM, Wagner B, Fischer H, Parrilla I, Schuler F, Rogers-Evans M, Muller K (2010) Oxetanes in drug discovery: structural and synthetic insights. J Med Chem 53:3227–3246PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, New York 2014

Authors and Affiliations

  • Francesco Colizzi
    • 1
  • Anne-Marie Lamontagne
    • 2
  • Daniel A. Lafontaine
    • 2
  • Giovanni Bussi
    • 1
  1. 1.Scuola Internazionale Superiore di Studi AvanzatiTriesteItaly
  2. 2.RNA Group, Department of Biology, Faculty of ScienceUniversité de SherbrookeSherbrookeCanada

Personalised recommendations